JP2022509156A5 - - Google Patents
Info
- Publication number
- JP2022509156A5 JP2022509156A5 JP2021528960A JP2021528960A JP2022509156A5 JP 2022509156 A5 JP2022509156 A5 JP 2022509156A5 JP 2021528960 A JP2021528960 A JP 2021528960A JP 2021528960 A JP2021528960 A JP 2021528960A JP 2022509156 A5 JP2022509156 A5 JP 2022509156A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- variable region
- chain variable
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811448228.1 | 2018-11-30 | ||
| CN201811448228 | 2018-11-30 | ||
| PCT/CN2019/121941 WO2020108611A1 (zh) | 2018-11-30 | 2019-11-29 | 抗cd40抗体、其抗原结合片段及其医药用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022509156A JP2022509156A (ja) | 2022-01-20 |
| JP2022509156A5 true JP2022509156A5 (https=) | 2023-02-13 |
Family
ID=70851924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021528960A Pending JP2022509156A (ja) | 2018-11-30 | 2019-11-29 | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220025060A1 (https=) |
| EP (1) | EP3892634A4 (https=) |
| JP (1) | JP2022509156A (https=) |
| KR (1) | KR20210099027A (https=) |
| CN (1) | CN112969714B (https=) |
| AU (1) | AU2019389354A1 (https=) |
| BR (1) | BR112021009835A2 (https=) |
| CA (1) | CA3120793A1 (https=) |
| MX (1) | MX2021005823A (https=) |
| TW (1) | TW202039558A (https=) |
| WO (1) | WO2020108611A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022332499A1 (en) | 2021-08-24 | 2024-03-21 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Fap/cd40 binding molecule and medicinal use thereof |
| EP4482873A1 (en) * | 2022-02-21 | 2025-01-01 | Concept to Medicine Biotech Co., Ltd. | Tumor antigen-dependent cd40 agonist antibodies |
| CN114573698B (zh) * | 2022-03-16 | 2023-01-06 | 沈阳三生制药有限责任公司 | 一种FcRn抗原结合蛋白及其制备方法和应用 |
| WO2023186111A1 (zh) * | 2022-04-02 | 2023-10-05 | 和铂医药(上海)有限责任公司 | 一种靶向cd40的抗原结合蛋白及其制备和应用 |
| KR20250019077A (ko) | 2022-05-31 | 2025-02-07 | 퓨쳐진 바이오파머쓰티컬 (베이징) 코., 엘티디. | 항-cd40 항체 및 항-pd-l1×cd40 이중특이성 항체 및 이의 용도 |
| CN117229396A (zh) * | 2022-06-06 | 2023-12-15 | 普米斯生物技术(珠海)有限公司 | 抗cd40抗体及其用途 |
| WO2024076969A1 (en) * | 2022-10-04 | 2024-04-11 | Memorial Sloan-Kettering Cancer Center | Anti-cd40 antibodies and uses thereof |
| TW202432588A (zh) | 2022-12-28 | 2024-08-16 | 大陸商蘇州盛迪亞生物醫藥有限公司 | 一種cd40結合分子的組成物及醫藥用途 |
| WO2024155778A2 (en) * | 2023-01-18 | 2024-07-25 | Michael Kaleko | Ph-selective antibody-based checkpoint inhibitors for conditional antibody-dependent cellular cytotoxicity |
| KR20250153216A (ko) | 2023-02-24 | 2025-10-24 | 상하이 맙젠 바이오텍 리미티드 | Fap/cd40 결합 분자의 약학적 조성물 및 이의 의약적 용도 |
| TW202436358A (zh) | 2023-03-01 | 2024-09-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｆａｐ／４－１ｂｂ／ｃｄ４０結合分子及其醫藥用途 |
| CN117924488A (zh) * | 2023-12-13 | 2024-04-26 | 合肥天港免疫药物有限公司 | 阻断性cd40抗体及其应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10308991A (ja) | 1997-05-07 | 1998-11-17 | Mitsubishi Electric Corp | スピーカー取付構造 |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| US20030059427A1 (en) | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| EP1322383B9 (en) | 2000-10-02 | 2006-09-06 | Chiron Corporation | Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| CA2658221C (en) * | 2001-04-27 | 2012-11-27 | Kyowa Kirin Co., Ltd. | Anti-cd40 monoclonal antibody |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| CN1922316B (zh) * | 2003-12-25 | 2011-03-23 | 协和发酵麒麟株式会社 | 抗cd40抗体突变体 |
| WO2006073443A2 (en) | 2004-04-27 | 2006-07-13 | Novartis Vaccines And Diagnostics, Inc. | Antagonist anti-cd40 monoclonal antibodies and methods for their use |
| US20070292439A1 (en) * | 2004-04-27 | 2007-12-20 | Novartis Vaccines And Diagnostics, Inc. | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
| EP2471813B1 (en) | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
| US8303955B2 (en) | 2005-05-26 | 2012-11-06 | Seattle Genetics, Inc. | Humanized anti-CD40 antibodies and their methods of use |
| EP1854810A1 (en) | 2006-05-09 | 2007-11-14 | PanGenetics B.V. | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
| EP2176298B1 (en) | 2007-05-30 | 2017-11-15 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| HUE049849T2 (hu) * | 2010-03-31 | 2020-10-28 | Boehringer Ingelheim Int | Anti-CD40 antitestek |
| EP2566514A4 (en) * | 2010-05-03 | 2013-11-27 | Abbvie Inc | METHODS OF INHIBITING FIBROSIS WITH ANTI-PAI-1 ANTIBODIES |
| HUE038848T2 (hu) * | 2011-04-21 | 2018-11-28 | Bristol Myers Squibb Co | CD40-antagonista antitest polipeptidek |
| ES2709654T3 (es) * | 2011-04-29 | 2019-04-17 | Apexigen Inc | Anticuerpos anti-CD40 y métodos de uso |
| GB201115280D0 (en) | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| KR102270618B1 (ko) | 2012-10-30 | 2021-06-30 | 아펙시젠, 인코포레이티드 | 항-cd40 항체 및 사용 방법 |
| JP6594855B2 (ja) | 2013-03-15 | 2019-10-23 | ゼンコア インコーポレイテッド | ヘテロ二量体タンパク質 |
| WO2015009853A1 (en) | 2013-07-16 | 2015-01-22 | University Of Louisville Research Foundation, Inc. | Compositions for mucusal delivery, useful for treating papillomavirus infections |
| GB201322583D0 (en) * | 2013-12-19 | 2014-02-05 | Alligator Bioscience Ab | Antibodies |
| CA2957146A1 (en) * | 2014-08-12 | 2016-02-18 | Alligator Bioscience Ab | Combination therapies with anti cd40 antibodies |
| AU2016249981B2 (en) * | 2015-04-13 | 2022-02-17 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| CN107810198B (zh) | 2015-05-29 | 2021-09-03 | 艾伯维公司 | 抗cd40抗体及其用途 |
| BR112017027549A2 (pt) * | 2015-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | anticorpo para cd40 |
| CN107922500A (zh) * | 2015-06-29 | 2018-04-17 | 洛克菲勒大学 | 具有增强的激动剂活性的抗cd40抗体 |
| BR112018004296B1 (pt) | 2015-09-04 | 2020-05-05 | Primatope Therapeutics Inc | anticorpos anti-cd40 humanizados e usos dos mesmos |
| CN106957366B (zh) * | 2016-01-12 | 2022-02-01 | 上海昀怡健康科技发展有限公司 | 一种C5aR抗体及其制备方法和应用 |
| TWI761348B (zh) * | 2016-05-27 | 2022-04-21 | 美商艾伯維生物醫療股份有限公司 | 抗cd40抗體及其用途 |
| AU2017310027A1 (en) * | 2016-08-12 | 2019-01-31 | Merck Patent Gmbh | Combination therapy for cancer |
| MX2019011635A (es) * | 2017-03-30 | 2020-01-20 | Jiangsu Hengrui Medicine Co | Método para la preparación de conjugados anticuerpo-fármaco. |
| AU2018278051A1 (en) * | 2017-06-01 | 2020-01-30 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof |
-
2019
- 2019-11-29 BR BR112021009835-6A patent/BR112021009835A2/pt not_active IP Right Cessation
- 2019-11-29 CA CA3120793A patent/CA3120793A1/en active Pending
- 2019-11-29 US US17/296,519 patent/US20220025060A1/en not_active Abandoned
- 2019-11-29 CN CN201980072271.9A patent/CN112969714B/zh active Active
- 2019-11-29 TW TW108143719A patent/TW202039558A/zh unknown
- 2019-11-29 JP JP2021528960A patent/JP2022509156A/ja active Pending
- 2019-11-29 KR KR1020217019296A patent/KR20210099027A/ko not_active Ceased
- 2019-11-29 WO PCT/CN2019/121941 patent/WO2020108611A1/zh not_active Ceased
- 2019-11-29 EP EP19891086.1A patent/EP3892634A4/en not_active Withdrawn
- 2019-11-29 AU AU2019389354A patent/AU2019389354A1/en not_active Abandoned
- 2019-11-29 MX MX2021005823A patent/MX2021005823A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022509156A5 (https=) | ||
| CN110352200B (zh) | 抗具有Ig和ITIM结构域的T细胞免疫受体(TIGIT)的抗体及其应用 | |
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| RU2739617C2 (ru) | Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками flt3 | |
| RU2018145852A (ru) | Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение | |
| RU2019141289A (ru) | АНТИ-SIRPα АНТИТЕЛА | |
| US20200347130A1 (en) | CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof | |
| BR112021005868A2 (pt) | Anticorpos anti-hla-g, composições compreendendo anticorpos anti-hla-g e métodos de uso de anticorpos anti-hla-g | |
| KR20190117493A (ko) | 항 pd-1 항체 및 그의 용도 | |
| JP2017149720A5 (https=) | ||
| RU2020127196A (ru) | Антитело против 4-1bb, его антигенсвязывающий фрагмент и его медицинское применение | |
| JP2012509881A5 (https=) | ||
| US11851460B2 (en) | PD1 binding agents | |
| TW201041592A (en) | Anti-TNF-α antibodies and their uses | |
| CN112969714A (zh) | 抗cd40抗体、其抗原结合片段及其医药用途 | |
| JP2022533538A5 (https=) | ||
| JP2015503909A5 (https=) | ||
| JP2012532851A5 (https=) | ||
| CN112513094A (zh) | 结合人her2的抗体、其制备方法和用途 | |
| AU2016334290B2 (en) | Antibody to hepatitis B surface antigen and use thereof | |
| JP2020521504A (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| US20250179195A1 (en) | Anti-flt3 antibodies and compositions | |
| CN116059341A (zh) | 药物组合物及用途 | |
| KR20230117183A (ko) | 새로운 종양 인게이저 치료 약물의 개발 및 이의 용도 | |
| JP2026507021A (ja) | Ｆａｐ／ｃｄ４０結合分子の医薬組成物及びその医薬的使用 |